Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
By Rob Curran
Biotech company Mersana Therapeutics said the Food and Drug Administration lifted a clinical hold on a Phase 1 trial of one of its cancer-treatment candidates.
In March, Mersana said the Food and Drug Administration had issued a clinical hold on the early-stage trial of the gastric-cancer drug candidate because of serious adverse effects.
Based on a review of data, Mersana lowered the starting dose in the Phase 1 dose escalation design, the company said.
In July, Mersana Therapeutics launched a broad restructuring following the failure of its lead product candidate in a late-stage study.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
October 31, 2023 08:52 ET (12:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks